Good MorningEquity markets slowed their declines, but new lows were set on Thursday. The move lower may have ended, but there is a risk that it will deepen before the bottom is hit. The market is repricing the odds of FOMC rate cuts, which will have far-reaching ramifications for stocks. The takeaway is that the outlook for earnings growth in the 2nd half is flawed.
The best target for solid support for the S&P 500 is near 4,800 and the prior all-time highs. That level is a significant pivot crossed earlier this year that has yet to be confirmed as support. If support is confirmed, new all-time highs are likely by the end of the year. If not, this market could sell off for several months and be down 20% to 30% from its highs.
Featured: Trump goes "all-in" on Grand Canyon energy breakthrough (Ad) 
|
Consumer Staples | |
Thinking about investing in PepsiCo? PepsiCo (NASDAQ: PEP) is the world’s 2nd largest consumer food company behind Nestle. It is the US's largest consumer food company, growing domestically and internationally. It is an attractive stock for many reasons.
The company's deeply rooted history... Read the Full Story |
|
From Our Partners | | Matt Monaco started with a $2,000 trading account and no clear strategy. After two years of trial and error, he crossed $1 million in 2020.
Today his account sits at $3 million, generating roughly $100,000 a month using a repeatable system he calls The Income Blueprint.
He's revealing the exact five-step scan and three trading lanes behind it in a free live training. | | Reserve your seat and claim The Income Blueprint free |
|
Industrials | |
CSX Corporation (NASDAQ: CSX) is a leading North American freight railroad operator. The railroad and railway sub-sector operates within the broader transportation sector. CSX’s earnings report was recently released and exceeded market expectations in its first quarter of 2024. The company's... Read the Full Story |
|
Markets | |
A new business cycle is underway for the United States economy, and the manufacturing sector could be in play. This time, it isn't only Wall Street pushing the bets forward but also the current administration's attempt to onshore some global steel and aluminum manufacturing jobs.
So far, markets ... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Markets | |
As investors search for safe havens in volatile markets, bear market funds are gaining popularity as a diversified asset class designed to withstand exceptionally volatile markets. While bear market funds can be appealing during periods of economic downturn due to their potential to produce return... Read the Full Story |
|
Consumer Discretionary | |
In 2024, Tesla (NASDAQ: TSLA) finds itself navigating through a year filled with turbulence, starkly contrasting its historical performance as a leader in the electric vehicle and technology sectors. With shares plummeting, Tesla now holds the unfortunate title of being the worst-performing S&... Read the Full Story |
|
From Our Partners | | Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film.
Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | | Watch the full investigation and decide for yourself |
|
Consumer Discretionary | |
As many reasons as there are to be skeptical of the rally in homebuilder stocks, names like D.R. Horton (NYSE: DHI) are trending higher and will continue to rise. They rise because the industry normalized and the business provides value for shareholders. That’s a blunt way of putting it, but... Read the Full Story |
|
Technology | |
In last week’s stock options article, we reviewed the pros and cons of debit spreads. When you believe a stock is going higher but want to limit your downside risk and are willing to cap upside gains to spend less on the trade, then a call debit spread can be a viable choice. In the same vei... Read the Full Story |
|
Communication Services | |
After having one of the best two-year performances in the technology sector, shares of Netflix Inc. (NASDAQ: NFLX) are at an inflection point. Markets may wonder whether the stock will make a new all-time high or give up some of the stellar gains it gave investors after the COVID-19 pandemic.
Wit... Read the Full Story |
|
Technology | | Stock buybacks, also called stock repurchases, are important drivers of shareholder value, which is one of the reasons why Marketbeat tracks the data. As the name suggests, a buyback is when a company buys back its own shares from the market.
Buybacks are a form of capital return that can offset t... Read the Full Story |
|
Industrials | |
Artificial intelligence (AI) is propping up the computer and technology sector, but it's also helping many other industries involved in collecting, procuring and providing real-time data. Planet Labs PBC (NYSE: PL), which was started by NASA scientists in 2010, operates a network of over 200 sate... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts. | | View Today's Stock Pick |
|
